S

Shandong Boan Biotechnology Co Ltd
HKEX:6955

Watchlist Manager
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Watchlist
Price: 8.86 HKD 0.91% Market Closed
Market Cap: 4.7B HKD
Have any thoughts about
Shandong Boan Biotechnology Co Ltd?
Write Note

Shandong Boan Biotechnology Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shandong Boan Biotechnology Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Operating Income
-ÂĄ106.4m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ8.8B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Operating Income
-ÂĄ1.1B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
ÂĄ4.3B
CAGR 3-Years
-27%
CAGR 5-Years
11%
CAGR 10-Years
42%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Income
ÂĄ2.1B
CAGR 3-Years
64%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Shandong Boan Biotechnology Co Ltd
Glance View

Market Cap
4.5B HKD
Industry
Biotechnology

Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.

Intrinsic Value
12.74 HKD
Undervaluation 30%
Intrinsic Value
Price
S

See Also

What is Shandong Boan Biotechnology Co Ltd's Operating Income?
Operating Income
-106.4m CNY

Based on the financial report for Dec 31, 2023, Shandong Boan Biotechnology Co Ltd's Operating Income amounts to -106.4m CNY.

What is Shandong Boan Biotechnology Co Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
23%

Over the last year, the Operating Income growth was 67%. The average annual Operating Income growth rates for Shandong Boan Biotechnology Co Ltd have been 23% over the past three years .

Back to Top